NasdaqCM - Nasdaq Real Time Price USD

Catalyst Pharmaceuticals, Inc. (CPRX)

Compare

21.92

-0.88

(-3.86%)

At close: January 10 at 4:00:01 PM EST

21.74

-0.18

(-0.82%)

After hours: 7:59:44 PM EST

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks yesterday

CPRX
-3.86%
IONS
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Investor's Business Daily 2 days ago

CPRX
-3.86%
TEVA

TEVJF
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a

GlobeNewswire 2 days ago

CPRX
-3.86%
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 3 days ago

CPRX
-3.86%
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 7 days ago

CPRX
-3.86%
Arcellx Stock Earns 82 Relative Strength Rating

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Investor's Business Daily 14 days ago

ADMA
0.00%
ACLX

CPRX
-3.86%
Neurocrine Biosciences Stock Sees RS Rating Upgrade

A Relative Strength Rating upgrade for Neurocrine Biosciences shows improving technical performance. Will it continue?

Investor's Business Daily 17 days ago

CPRX
-3.86%
NBIX
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 17 days ago

CPRX
-3.86%
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 23 days ago

CPRX
-3.86%
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA. 43r

GlobeNewswire 25 days ago

CPRX
-3.86%
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investor's Business Daily 30 days ago

ADMA
0.00%
CORT
-3.56%
CPRX
-3.86%
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

CPRX
-3.86%
CTLT
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 14...

Simply Wall St. last month

CPRX
-3.86%
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks last month

CPRX
-3.86%
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks last month

CPRX
-3.86%
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial ExecutionCORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award w

GlobeNewswire last month

CPRX
-3.86%
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed belo

GlobeNewswire last month

CPRX
-3.86%
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as

GlobeNewswire last month

CPRX
-3.86%
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point

When companies post strong earnings, the stock generally performs well, just like Catalyst Pharmaceuticals, Inc.'s...

Simply Wall St. last month

CPRX
-3.86%
Vericel Stock Sees RS Rating Shoot Higher

A Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue?

Investor's Business Daily last month

ADMA
0.00%
VCEL

CPRX
-3.86%

Performance Overview

Return	CPRX	S&P 500
YTD	+4.03%	-1.35%
1-Year	+43.36%	+22.51%
3-Year	+234.15%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Arcellx Stock Earns 82 Relative Strength Rating

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point

Vericel Stock Sees RS Rating Shoot Higher

Performance Overview